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Summary
Orthotopic liver transplantation (OLT) with donation after circulatory death
(DCD) often leads to a higher first week peak alanine aminotransferase (ALT)
and a higher rate of biliary nonanastomotic strictures (NAS) as compared to
donation after brain death (DBD). This retrospective study was to evaluate
whether an association exists between peak ALT and the development of NAS in
OLT with livers from DBD (n = 399) or DCD (n = 97) from two transplantation
centers. Optimal cutoff value of peak ALT for risk of development of NAS post-
DCD-OLT was 1300 IU/l. The 4-year cumulative incidence of NAS after DCD-
OLT was 49.5% in patients with a high ALT peak post-OLT, compared with
11.3% in patients with a low ALT peak. (P < 0.001). No relation between peak
ALT and NAS was observed after DBD-OLT. Multivariate analysis revealed peak
ALT ≥1300 IU/l [adjusted hazard ratio (aHR) = 3.71, confidence interval (CI)
(1.26–10.91)] and donor age [aHR = 1.04, CI 1.00–1.07] to be independently
associated with development of NAS post-DCD-OLT. A peak ALT of <1300 IU/l
carries a risk for NAS similar to DBD-OLT. Thus, in DCD-OLT, but not in DBD-
OLT, peak ALT discriminates patients at high or low risk for NAS.
Introduction
Orthotopic liver transplantation (OLT) has evolved into a
routine treatment for advanced liver disease with excellent
short- and long-term survival [1,2]. An increasing number
of patients eligible for liver transplantation and a decreasing
number of donors after brain death (DBD) have led to the
extension of criteria for acceptance of potential liver grafts
in the last decade [3,4]. OLT with livers from donation
after circulatory death (DCD) has become common in the
Netherlands and the United Kingdom. However, OLT with
a liver from a DCD donor carries a high risk for develop-
ment of nonanastomotic biliary strictures (NAS) [5]. NAS
can occur in up to 13–34% after OLT with a DCD donor
and is considered a major cause of morbidity and reduced
graft survival [6–8]. Early recognition of an increased risk
to develop NAS may be valuable for timely intervention.
Besides genetic factors, such as CCR5D32 and matrix-
metalloproteinase 2 polymorphism, several ischemic
parameters have been related to the development of NAS.
For example, cold ischemia time (CIT) and warm ischemia
times have been described as potential predictors of NAS in
DCD and DBD donors, but clinical use of these parameters
for predicting NAS has remained controversial [9–13].
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Livers from DCD have an inevitable donor warm ischemia
time (DWIT) between cardiac arrest and organ preserva-
tion, which may lead to a higher degree of ischemia–reper-
fusion injury (IRI) in the first week after OLT. It is likely
that the higher incidence of NAS after OLT with DCD liv-
ers is largely the results of the additional ischemia–reperfu-
sion injury due to the DWIT [14–16]. We therefore
hypothesized that a relation may exist between injury of the
liver parenchyma, reflected by first week post-OLT peak
aminotransferases, and the risk for NAS development dur-
ing follow-up, especially after DCD-OLT, as evaluated in a
cohort from two independent centers.
Materials and methods
A total of 519 first consecutive OLTs for chronic liver dis-
eases were performed in two liver transplantation centers.
After exclusion of 23 patients with primary nonfunction or
a minimum follow-up of <7 days, 496 patients were
included in the analysis. From the Leiden University Medi-
cal Center (LUMC, center A), a total of 174 OLTs could be
included in the time period of October 2001 until March
2011 next to 322 OLTs from the University Medical Center
Groningen (UMCG, center B) performed in the time per-
iod of July 2000 until June 2012. This included OLTs using
livers from DBD as well as DCD donors (Fig. 1). Patient
follow-up was determined as time of transplantation until
the first occurring event (i.e., development of NAS, retrans-
plantation, or death) or in case of no event, until July 2012.
In 2001, a national protocol was introduced in the Neth-
erlands regarding the acceptance of organs from donation
after circulatory death [17]. In this protocol, only Maas-
tricht category 3 donors below 55 years of age, with a
DWIT below 30 min, a maximum of 15 min between
respiratory withdrawal and cardiac arrest, a body mass
index of <28, and a mean arterial pressure of <50 mm Hg
for maximum 15 min before cardiac arrest were accepted.
DCD donors were therefore selected in both centers
according to this protocol.
Donor surgery
In case of DCD donors, a DWIT was measured, defined as
the time between circulatory arrest and cold flush with
preservation fluid in the donor. Cold ischemia time was
defined as the time between cold flush with preservation
fluid in the donor and removal of the liver from ice during
the transplantation procedure. The recipient warm ische-
mia time was defined as the time of removal of the donor
liver from ice until reperfusion of the donor liver in the
recipient. In both centers, University of Wisconsin (UW)
preservation fluid was used to flush out DBD liver grafts
and in case of DCD liver grafts mainly histidine–trypto-
phan–ketoglutarate (HTK) was used.
Recipient surgery and routine follow-up
In both centers, OLT with standard technique of ‘piggy-
back’ cavo-caval anastomosis, porto-portal and hepatic
artery to hepatic artery anastomosis was performed in
most recipients. In some cases, the hepatic artery was
anastomosed to the aorta via an iliac conduit. A duct-to-
Figure 1 Flowchart of patient inclusion and exclusion.
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duct biliary anastomosis—over a 8–12 Ch stent in center
A, no stent in center B—was performed if possible. The
biliary stent was removed endoscopically with endoscopic
retrograde cholangiography (ERC) at 6 weeks or earlier as
indicated. In general, post-transplantation care for both
centers was comparable. Centers only differed in the use
of prophylactic antibiotics, as was previously described
[18]. In center A, a combination of gentamicin,
cefuroxime, penicillin G, and metronidazole was used with
an additional 3 weeks of selective digestive tract decon-
tamination (polymyxin/neomycin, norfloxacin and amfo-
tericin B). In center B, patients received prophylactic
amoxicillin–clavulanate and ciprofloxacin. In the first year,
blood liver biochemistry was performed daily in the first
2 weeks, weekly in the following 2 weeks, monthly there-
after in the first year, and then every 3 months. In both
cohorts, ultrasound (US) was performed routinely on day
0, 1, and 7, and subsequently at 3, 6, 12 months, and
yearly after OLT. ERC or magnetic resonance cholangiog-
raphy (MRC) and other imaging studies were performed
when indicated. A liver biopsy was performed per protocol
at 6 months in center A and further as indicated in both
centers. Pre-OLT baseline parameters, including laboratory
model for end-stage liver disease (MELD) scores, were
evaluated (n = 449). Due to missing variables, 49 MELD
scores could not be computed (center A n = 7, center B
n = 41).
IRI and NAS
The degree of both ischemic and reperfusion hepatocel-
lular injury was evaluated by postoperative serum levels
of alanine aminotransferase (ALT). Serum ALT was
determined during the seven consecutive days after OLT
and measured by routine biochemical methods. The
highest level of the first peak ALT was evaluated indi-
vidually. As there is no clear definition of NAS in the
literature, we have used the definition with the most
clinical relevance. NAS was defined as follows: any trea-
ted stricture or irregularity of the intra- or extrahepatic
bile ducts occurring at least 1 cm above the anastomosis
post-OLT. Analysis of NAS development was performed
in both the combined cohort as well as the individual
cohorts. For timing, the first endoscopic or percutane-
ous treatment for NAS, that is, balloon dilatation and/
or a performed stenting procedure, was used. Nonanas-
tomotic biliary strictures that did not require interven-
tion and anastomotic strictures were not included in the
definition of NAS for the current study. Because of a
different pathophysiological mechanisms, biliary stric-
tures as a result from hepatic artery thrombosis or arte-
rial complications were not considered NAS and were
excluded.
Statistical analyses
Statistical analysis was performed using SPSS 20.0 (IBM,
Armonk, NY, USA). A Mann–Whitney U-test was used to
calculate differences in medians, and Fisher’s exact test was
performed for categorized variables. The optimal cutoff
value for peak ALT is defined as the point with the most
significant split for association with NAS or no NAS as
determined by log-rank test. Using the calculated cutoff
value, a peak ALT below this value was considered as mild
IRI, whereas a peak ALT above this value was considered as
severe IRI. Cumulative incidence curves were established
using one minus survival incidence rates according to the
Kaplan–Meier method, and risk factor analysis was per-
formed using univariate and multivariate stepwise forward
Cox regression analysis. In case of a P-value of <0.20 in the
univariate analysis, the parameter was taken into account
in the multivariate analysis. A P-value of <0.05 was consid-
ered statistically significant.
Retrospective studies are approved by the institutional
review board by legislation, and the study was performed
according to the guidelines of the Helsinki and the Istanbul
declaration.
Results
A total number of 496 OLTs with a minimum follow-up of
7 days were performed in both centers, with 399 DBD
donor livers and 97 DCD donor livers. Median follow-up
from OLT until development of NAS was 4.4 months
(range 0.3–58). Donor and recipient variables are presented
in Table 1.
Donor and surgical variables
Median donor age for DCD donors was significantly lower
compared with DBD donors in the combined cohort (44
vs. 50 years, respectively, P < 0.001). CIT was shorter for
DCD donors than for DBD donors (DCD 460 min vs.
DBD 503 min; P = 0.003), but recipient warm ischemia
time (RWIT) did not differ for both types of donors
(P = 0.44). In case of DCD-OLT, median donor warm
ischemia time from cardiac arrest to flush (DWIT) was
17 min. As DWIT is considered a risk factor for the devel-
opment of NAS, DWIT was evaluated separately for
patients who developed NAS and patients without NAS;
however, this was not significantly different (NAS 17 min
vs. no NAS 16 min, P = 0.62).
To evaluate injury of the liver parenchyma, peak ALT
was evaluated. The median time point of the first peak ALT
was found to be at 1 day after OLT. Median peak ALT was
significantly higher after OLT using DCD donors than after
DBD-OLT (DCD 1525 IU/l vs. DBD 719 IU/l; P < 0.001).
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Similar results were observed for median peak aspartate
aminotransferase (AST) (DCD 2557 IU/l vs. DBD
1006 IU/l; P < 0.001). For each cohort individually, similar
results were obtained (data not shown). Because of the
strong correlation between peak AST and peak ALT (Pear-
son’s coefficient = 0.86, P < 0.001) and a more explicit
cutoff value and higher AUC in the receiver operating char-
acteristic (ROC) curve for peak ALT, further analysis was
performed for peak ALT only.
Other serum markers, such as bilirubin, alkaline phos-
phatase, and gamma-glutamyltransferase, were not
included in the analyses because no optimal cutoff value
could be determined.
To determine the potential influence of blood transfu-
sion and kidney function on peak ALT level, correlation
tests were performed. However, no correlation was found
between peak ALT and creatinine level (P = 0.715) or esti-
mated glomerular filtration rate (P = 0.400) and between
peak ALT and the volume of erythrocyte, fresh frozen
plasma, and cellsaver transfusion (P = 0.284, P = 0.173,
and P = 0.241, respectively).
IRI and NAS
In the combined cohorts, NAS developed in 31% after
DCD-OLT and in 13% after DBD-OLT (P < 0.001). The
incidence of NAS was not statistically different between
center A and center B (P = 0.37). Optimal cutoff value of
serum ALT for NAS was calculated using log-rank statistics
and a ROC curve for DCD-OLT (n = 97) and was estab-
lished at ≥1300 IU/l (Fig. 2a and b). Using the calculated
cutoff value, a low peak ALT of <1300 IU/l was considered
mild IRI, whereas a high peak ALT of ≥1300 IU/l was con-
sidered severe IRI. Using this cutoff point, sensitivity of
peak ALT level to predict NAS was 87%, specificity 54%,
the positive predictive value 46%, and the negative predic-
tive value 90%. A cutoff value of ≥1300 IU/l corresponded
with the highest Youden Index of 0.41 and a positive likeli-
hood ratio of 1.87. After DCD-OLT, severe IRI preceded
NAS development in 46% cases compared with 10% in the
mild IRI group (P < 0.001) (Table 2). Four-year cumula-
tive incidence of NAS development was 49.5% in case of
severe IRI compared with 11.3% when mild IRI occurred
(log rank P = 0.001; Fig. 3). In 11% of DCD-OLT cases, re-
transplantation for NAS was needed. When the cumulative
incidence was calculated for each cohort individually, simi-
lar results were obtained. In both cohorts, severe IRI was
significantly associated with NAS development after DCD-
OLT. (Data not shown) No optimal cutoff value of peak
ALT could be obtained for DBD-OLT. (Fig. 4) Therefore,
the threshold for severe IRI of ≥1300 IU/l was also applied
to the DBD cohort. However, no association could be
found between peak ALT ≥1300 IU/l and NAS after DBD-
OLT, neither in the individual cohorts nor in the combined
group (P = 0.74). Based on the cutoff value determined for
DCD-OLT, 4-year cumulative incidence of NAS after
DBD-OLT in the combined group was 14.3% when peak
ALT was ≥1300 IU/l compared with 13.7% when peak ALT
was <1300 IU/l (log rank P = 0.94).
Besides higher incidences of NAS, a peak ALT of
≥1300 IU/l was also associated with worse patient and graft
survival. Overall, mortality or retransplantation rate was
Table 1. Baseline characteristics. Data presented as median (range) for
continuous variables and percentage (number) for categorized
variables.
Characteristic DBD (n = 399) DCD (n = 97) P
Donor age
(median, range)
50 (14–86) 44 (14–65) <0.01
Donor gender % (n)
Male 49.4 (197) 60.8 (59) <0.05
Female 50.6 (202) 39.2 (38)
Recipient age
(median, range)
53 (17–70) 54 (19–69) 0.62
Recipient gender % (n)
Male 60.9 (243) 69.1 (67) 0.16
Female 39.1 (156) 30.9 (30)
MELD (median,
range)
16 (6–40) 14 (6–40) 0.42
Diagnosis pre-OLT % (n)
ALD 16.8 (67) 15.5 (15) 0.87
HCC 10.5 (42) 11.3 (11)
PSC 16.8 (67) 17.5 (17)
PBC 4.8 (19) 7.2 (7)
HBV 5.5 (22) 2.1 (2)
HCV 9.5 (38) 11.3 (11)
AIH 6.3 (25) 4.1 (4)
Metabolic 7.3 (29) 7.2 (7)
Other 22.6 (90) 23.7 (23)
NAS % (n) 13.3 (53) 30.9 (30) <0.01
CIT (median,
25–75% range)
503 (420–619) 460 (407–517) <0.01
RWIT (median,
25–75% range)






1006 (64–14750) 2557 (200–19590) <0.01
Peak ALT (median,
range)
719 (69–8242) 1525 (106–11105) <0.01
DBD, donation after brain death; DCD, donation after circulatory death;
MELD, model for end-stage liver disease; OLT, orthotopic liver trans-
plantation; ALD, alcoholic liver disease; HCC, hepatocellular carcinoma;
PSC, primary sclerosing cholangitis; PBC, primary biliary cirrhosis; HBV,
hepatitis B virus; HCV, hepatitis C virus; AIH, auto-immune hepatitis;
NAS, nonanastomotic biliary strictures; CIT, cold ischemia time (min);
RWIT, recipient warm ischemia time (min); DWIT, donor warm ischemia
time (min); AST, aspartate aminotransferase (IU/l); ALT, alanine amino-
transferase (IU/l). Statistically significant p-values are printed in bold.
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36% of the patients with severe IRI, as compared to 26% of
the patients with mild IRI (P = 0.03). Twenty-three
patients were previously excluded due to primary nonfunc-
tion of the graft, early mortality, and a follow-up of
<7 days. This included 16 DBD-OLTs (3.9% of all DBD-
OLT) and seven DCD-OLTs (6.7%). Ten of 16 DBD-OLTs
and six of seven DCD-OLTs had a peak ALT of ≥1300 IU/l,
indicating that severe IRI may also be associated with early
graft loss. Mortality within 1 month was 1.5% for the
patients with mild IRI and 4.2% for patients with severe
IRI (all after DBD-OLT), which did not differ between the
groups (P = 0.12).
Primary sclerosing cholangitis and NAS
Because radiodiagnostic features of NAS resemble the diag-
nostic criteria for primary sclerosing cholangitis (PSC), dis-
tinguishing NAS and recurrent PSC can be difficult,
especially late occurrence of NAS might in fact be recurrent
PSC. Therefore, the analysis was also performed after the
exclusion of all patients with PSC (n = 84). After the exclu-
sion of patients with PSC, the 4-year cumulative incidence
of NAS after DCD-OLT was 52.4% in case of severe IRI
compared with 13.5% when peak ALT was <1300 IU/l (log
rank P = 0.002). For DBD-OLT, 4-year cumulative inci-
dence was 9.0% when peak ALT was <1300 IU/l compared
with 11.4% IU/l when peak ALT was ≥1300 IU/l (log rank
P = 0.49).
Univariate and multivariate analysis
Cox regression analysis for risk of NAS development was
performed for OLT with DCD and DBD donors separately.
For DCD-OLT, donor age, MELD score, CIT, and peak
ALT ≥1300 were significantly associated with NAS in the
univariate analysis at the P < 0.20 value and were thus
included in the multivariate analysis. PSC as indication for
OLT, as well as the center at which OLT was performed,
was not associated with development of NAS in the univar-
iate analysis for DCD-OLT. Multivariate analysis showed
peak ALT ≥1300 and donor age to be independently associ-
ated factor for the development of NAS after DCD-OLT,
adjusted for MELD score and CIT (adjusted hazard ratio
(aHR) for peak ALT ≥1300 = 3.71, confidence interval
(CI) = 1.26–10.91, P = 0.017) (Table 3). Multivariate
analysis revealed PSC as indication for OLT to be the only
independently associated parameter for the development of
NAS after DBD-OLT (aHR = 2.37, CI 1.32–4.26,
P = 0.004) (Table 4).
Discussion
The present study describes a strong and independent asso-
ciation between a serum peak ALT of ≥1300 IU/l and the
development of NAS after liver transplantation with dona-
tion after circulatory death (DCD-OLT). A higher donor
Table 2. Development of NAS respective of degree of IRI. Numbers are
presented as % (n).
Graft type
Combined cohorts (center A and center B)
DBD DCD
No NAS NAS No NAS NAS
Mild IRI 86.2 (250) 13.8 (40) 90.0 (36) 10.0 (4)
Severe IRI 88.1 (96) 11.9 (13) 54.4 (31) 45.6 (26)
P = 0.74 P < 0.001
ALT, alanine aminotransferase; DBD, donation after brain death; DCD,
donation after circulatory death; NAS, nonanastomotic biliary strictures;
IRI, ischemia–reperfusion injury.
Mild IRI was defined as peak ALT ≤ 1300 IU/l and severe IRI as peak
ALT > 1300 IU/l. Statistically significant p-values are printed in bold.
(a)
(b)
Figure 2 (a) Optimal alanine aminotransferase (ALT) cutoff point for
nonanastomotic strictures (NAS) after donation after circulatory death
(DCD)-orthotopic liver transplantation (OLT). Calculation of the optimal
ALT cutoff (≥1300 IU/l) for prediction of NAS in DCD-OLT using the
combined cohorts. (b) receiver operating characteristic curve of peak
ALT for NAS after DCD-OLT.
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age was also independently associated with NAS after
DCD-OLT.
In the last decade, transplantation of livers from DCD
donors has become common in the Netherlands and Uni-
ted Kingdom to decrease wait-list mortality. However,
these grafts are known to be associated with higher compli-
cations rates, such as primary nonfunction, ischemia–rep-
erfusion injury, and nonhepatic complications such as the
development of end-stage renal disease during follow-up
after OLT [19,20]. It is therefore important to balance the
risk for post-transplant complications after DCD-OLT and
the survival benefit for an individual patient. In 2012, Jay
and al. reported improvements in effectiveness for DCD-
OLT when MELD scores were >15 as compared to lower
MELD scores. However, for patients with a MELD score of
15–20, a high cost-effectiveness ratio, due to high direct
medical costs, was reported [21]. The price of donation
after circulatory death was further discussed by van der
Hilst et al. [22]. That study described a significantly higher
cost per life year for DCD grafts, mainly due to a higher
complication rate and a longer ICU stay.
Similar patient survival was reported for DCD-OLT and
DBD-OLT after a national protocol for accepting DCD
organs was implemented in the Netherlands in 2001, with
currently 30–40% of OLTs with a DCD donor [17].
Biliary complications are among the most frequent
complications after DCD-OLT leading to considerable
morbidity and mortality. A recent meta-analysis of
O’Neill et al. [23] including 1619 patients with DCD-
OLT showed an odds ratio for biliary complications of
2.4 as compared to DBD-OLT. NAS is considered the
most challenging biliary complication because the stric-
tures are often located beyond the scope of endoscopic
treatment and resistant to therapy. It has been hypothe-
sized that IRI may play an important role in the devel-
opment of NAS. IRI is the combined result of ischemia,
reperfusion, status of the graft (e.g., steatosis or not),
and the immune reactions of the recipient during and
after reperfusion. DCD grafts are known to be more
prone to IRI due to an additional DWIT and to have
more biliary complications after OLT than DBD grafts
[24]. To reduce ischemic injury and hopefully compen-
sate for DWIT-induced injury, ischemia times, especially
cold ischemia time, are kept shorter for DCD-OLT com-
pared with DBD-OLT. However, ischemia times are not
indicative for injury induced during reperfusion, and
there is evidence that most IRI-induced hepatic injury
develops after restoration of blood flow, at least partially
Figure 3 Development of nonanastomotic strictures (NAS) post-orthotopic liver transplantation (OLT). Cumulative incidence (CLI) of NAS develop-
ment after OLT with livers from donation after cardiac death (DCD) reached 49.5% at 48 months when peak alanine aminotransferase (ALT)
≥1300 IU/l (n = 57) compared with 11.3% when peak ALT <1300 IU/l (n = 40) (P < 0.001). CLI rates of NAS after donation after brain death-OLT
did not differ between recipients with mild or severe ischemia–reperfusion injury (IRI) or DCD-OLT with peak ALT <1300 IU/l/. CLI rates were calcu-
lated using one minus survival incidence rates with the Kaplan–Meier test and compared using log-rank test.
Figure 4 Receiver operating characteristic (ROC) curve of peak
alanine aminotransferase (ALT) for nonanastomotic strictures (NAS)
after donation after brain death (DBD)-orthotopic liver transplantation
(OLT).
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due to an excess of reactive oxygen species [25,26].
Serum peaks of transaminases within the first 7 days
after OLT reflect, more than ischemia times, liver paren-
chyma injury as it includes both periods of ischemia and
reperfusion.
Orthotopic liver transplantation with DCD donors have
higher peak AST and ALT levels postoperatively than
DBD-OLT. The current data show that severe IRI, defined
as peak serum ALT ≥1300 IU/l post-OLT, is strongly asso-
ciated with the increased incidence of NAS after DCD-
OLT, with a 4-year cumulative incidence rate of NAS in
this group of 49.5%. In the multivariate analysis, peak
ALT ≥1300 IU/l was independently associated with the
development of NAS after DCD-OLT. Furthermore, our
study showed a higher donor age to be an independent
risk factor for the development of NAS after DCD-OLT.
This is an important finding as advancing age is generally
accepted to be associated with more hepatic steatosis,
whereas Baccarani et al. [27] described hepatic steatosis to
be a risk factor for post-transplant biliary complications.
However, donor age as a risk factor remains subject to
debate in previous studies. Whereas some studies showed
an advancing age to be associated with higher incidences
of NAS, others have reported similar results for DCD-
Table 3. Univariate and multivariate analysis of risk factors for development of NAS after DCD-OLT.
Variables DCD-OLT %
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Donor age
Continuous 1.04 (1.00–1.07) 0.01 1.04 (1.00–1.07) 0.04
Donor gender
Male 60.8 1.36 (0.65–2.85) 0.42
Female (reference) 39.2 1
Donor ICU stay (days)
Continuous 1.00 (0.85–1.18) 0.97
Recipient age at OLT
Continuous 1.01 (0.98–1.04) 0.65
Recipient gender
Male 69.1 1.21 (0.57–2.58) 0.62
Female (reference) 30.9 1
MELD score
Continuous 1.03 (0.97–1.07) 0.17 1.03 (0.99–1.07) 0.22
Peak ALT
Severe 58.8 4.90 (1.71–14.05) 0.003 3.71 (1.26–10.91) 0.02
Mild (reference) 41.2 1
DWIT
Continuous 1.01 (0.98–1.04) 0.49
CIT
Continuous 1.00 (1.00–1.01) 0.19 1.00 (1.00–1.01) 0.32
RWIT
Continuous 0.98 (0.94–1.02) 0.28
PSC as indication
Other (reference) 82.5 1
PSC 17.5 0.47 (0.14–1.55) 0.21
Study Center
Center B 60.8 0.66 (0.32–1.36) 0.26
Center A (reference) 39.2 1
Preservation solution
UW 33.0 1.06 (0.50–2.27) 0.88
HTK (reference) 67.0 1
MAP ≤ 55 mmHg (during reperfusion)
No 48.3 1.28 (0.54–3.02) 0.57
Yes (reference) 51.7 1
HR, hazard ratio; CI, confidence intervals; OLT, orthotopic liver transplantation; ICU, intensive care unit; MELD, model for end-stage liver disease; ALT,
alanine aminotransferase; DWIT, donor warm ischemia time; RWIT, recipient warm ischemia time; CIT, cold ischemia time; PSC, primary sclerosing
cholangitis; UW, University of Wisconsin; HTK, histidine–tryptophan–ketoglutarate; MAP, mean arterial pressure; DCD, donation after circulatory
death; NAS, nonanastomotic strictures. Statistically significant p-values are printed in bold.
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OLT when younger and older donors were compared
[7,8,28,29].
In literature, DWIT has also been associated with the
development of NAS. This may be the result of continued
energy consumption of the graft at body temperature dur-
ing DWIT. Due to an inadequate tissue perfusion, this
energy consumption may lead to adenosine triphosphate
depletion and a shift from aerobic to an anaerobic metabo-
lism, which may result in a more injured graft. In the pres-
ent study, likely due to a low variability of DWIT between
the patients, DWIT was not an independent risk factor.
DWIT was defined as the time between circulatory arrest
and cold flush with preservation fluid in the donor. This is
slightly different than some other studies where DWIT is
defined as the time between cessation of cardiopulmonary
support and cold flush [30]. However, the absolute time
period of DWIT is not the only risk factor of DWIT for the
development of NAS. Because of different characteristics of
the graft, such as steatosis and immune responses of the
donor and recipient, some grafts may be more prone to
injury from DWIT than others and the actual effect of
DWIT on the graft may be different even though the time
period is not different. Furthermore, Op den Dries et al.
[31] recently evaluated peribiliary plexus injury. DBD livers
showed a significantly higher percentage of grafts without
any peribiliary vascular plexus injury than DCD livers
(18% vs. 0%). Injury in the deep peribiliary glands was also
more severe and more prevalent in patients that developed
NAS, compared with patients without NAS.
We therefore hypothesize that the higher peak ALT and
increased incidence of NAS in a subgroup of DCD-OLT
patients are different presentations of the same ischemia–
reperfusion injury due to the DWIT combined with warm
ischemia between respiratory withdrawal and cardiac arrest
in the donor.
After DBD-OLT, peak ALT was not associated with the
development of NAS, whereas PSC was a risk factor in these
patients. After DCD-OLT with peak ALT below 1300 IU/l,
the risk of NAS was similar to DBD-OLT. Therefore, a peak
ALT below 1300 IU/l could be used as a negative predicting
factor in the extra risk for development of NAS after DCD-
OLT. Mangus et al. [32]. have recently demonstrated that
the pretransplant donor peak ALT is not related to post-
transplant ALT levels. Moreover, a higher donor peak ALT
Table 4. Univariate and multivariate analysis of risk factors for development of NAS after DBD-OLT.
Variables DBD-OLT %
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Donor age
Continuous 1.01 (0.99–1.03) 0.38
Donor gender
Male 49.4 0.95 (0.55–1.62) 0.85
Female (reference) 50.6 1
Recipient age at OLT
Continuous 0.99 (0.97–1.01) 0.15 0.99 (0.97–1.01) 0.25
Recipient gender
Male 60.9 1.89 (1.02–3.47) 0.04 1.82 (0.98–3.39) 0.06
Female (reference) 39.1 1
MELD score
Continuous 1.00 (0.97–1.04) 0.89
Peak ALT
Mild (reference) 72.7 1
Severe 27.3 1.03 (0.55–1.92) 0.94
CIT
Continuous 1.00 (1.00–1.00) 0.77
RWIT
Continuous 1.01 (0.99–1.04) 0.34
PSC as indication
Other (reference) 83.2 1
PSC 16.8 2.71 (1.53–4.78) 0.001 2.37 (1.32–4.26) 0.004
Study Center
Center B 65.9 1.29 (0.71–2.34) 0.41
Center A(reference) 34.1 1
HR, hazard ratio; CI, confidence intervals; OLT, orthotopic liver transplantation; MELD, model for end-stage liver disease; ALT, alanine aminotransfer-
ase; DWIT, donor warm ischemia time; RWIT, recipient warm ischemia time; CIT, cold ischemia time; PSC, primary sclerosing cholangitis; DBD, dona-
tion after brain death; NAS, nonanastomotic strictures. Statistically significant p-values are printed in bold.
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was not indicative for early graft function and 1-year sur-
vival. Close monitoring of recipient peak ALT may there-
fore be an important first marker to predict clinical patient
and graft outcome after transplantation and allow a more
intensive follow-up.
Reducing IRI in DCD-OLT to the extent that peak ALT
is below 1300 IU/l will probably diminish the incidence of
NAS to the incidence after DBD-OLT (14%), but may not
completely eliminate NAS, as other pathophysiological
mechanisms might be involved. This is consistent with the
idea that NAS is most likely the result of a complex mecha-
nism involving ischemic, immunologic, and toxic processes
which all affect the biliary tree or its vascular supply [33–
35]. Current preservation solutions and techniques may be
insufficient [36]. Several attempts are being made to
improve preservation and reduce IRI of liver grafts using
machine liver perfusion and/or abdominal regional perfu-
sion, but also fibrinolytic agents are used to dissolve possi-
ble microthrombi in the donor liver [37–39].
The current study has certain limitations. The sample
size is relatively small. It is clear that these novel findings
need to be replicated in larger cohorts. Furthermore, we
used only ALT and not AST as marker for IRI occurring in
the liver, as AST is derived from mitochondria in liver cells
but is also produced in heart, skeletal muscles, and brain
cells. After surgery, AST can also be elevated due to damage
of the abdominal muscles during surgery, and this makes it
less specific as a parameter of IRI after OLT. However, most
cases of NAS developed within the first 6 months after
OLT. Whether a more intensive follow-up and earlier inter-
vention in patients with high peak ALT after DCD-OLT
might prevent retransplantation remains to be established.
In conclusion, our data show that serum peak ALT
≥1300 IU/l and a higher donor age are strongly and inde-
pendently associated with the development of clinically
relevant NAS after DCD-OLT, with peak ALT below
1300 IU/l predicting a risk similar to DBD-OLT. In DCD-
OLT, it can thus be used in classifying patients as high risk
or low risk (similar to DBD-OLT) for developing NAS. The
current data indicate that the higher risk of NAS after DCD
as compared to DBD is likely the result of cases of DCD-
OLT with more severe IRI due to warm ischemia in the
donor. This enables the use of peak ALT below 1300 IU/l
as target for future interventions aimed at prevention of
NAS and a peak ALT of ≥1300 IU/l as a justification for a
more intensive follow-up in DCD-OLT.
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